text_1: Hepatitis C Drug Raises Cure Rate in Late Trial
text_2: "This is basically a stock market performance story dressed up as a clinical trial story, one of many such stories where someone on the business desk is asked to write about a ""breakthrough"" for the purposes of giving investors/readers some insight on where to make their next investment move. Because the reporter is well above average, the story is packed with information about the trial, about the drug, about hepatitis and about the company. But there is quite a bit of information missing that would be helpful for patients who, most likely, aren’t going to see perhaps unfounded hope in phrases such as, ""a new era in treating a sometimes fatal disease."" Even in a stock market story, it is important to get the clinical part right. And, especially in a stock market story, it is important to get the cost part right."